All News

A meta-analysis found β-blockers did not improve clinical outcomes in patients with acute MI and preserved LVEF, raising questions about routine use.

Patients with myasthenia gravis experience significantly higher rates of urinary incontinence and overactive bladder symptoms, impacting their quality of life.

Smart pill bottles may boost adherence to oral breast cancer therapies through daily reminders and tracking, though cost and technology barriers remain, says Steven Manobianco, MD.

The most pressing questions in ITP involve finding a cure and developing treatments safe for use during pregnancy.

These results were presented during the press briefing ahead of the 2026 American Society of Clinical Oncology Gastrointestinal Cancers Symposium.

Nimbus Therapeutics and Eli Lilly announce their partnership to develop a novel oral drug for patients with obesity and other metabolic disorders.

Multidisciplinary care enhances kidney health and cardiovascular outcomes, but more research into models is needed, said Roy Mathew, MD.

Population demographics and prevention efforts are key drivers of influenza burden, according to Marco del Riccio, MD.

Peter Voorhees, MD, emphasizes the importance of carefully determined early regimens for smoldering myeloma and involving patients in treatment decisions.

Economic stability and social factors significantly influence the risk of pediatric long COVID, highlighting the need for targeted health interventions.

The treatment was compared with adagrasib in second- and subsequent-line treatment, with sotarasib coming out on top based on current efficacy data.

A study shows falling CRLM incidence and improved survival for synchronous disease, with persistent gaps for metachronous metastases.

GoodRx offers affordable access to oral semaglutide for weight loss through telemedicine, simplifying treatment options and pricing for consumers.

Rilzabrutinib (Wayrilz; Sanofi), a BTK inhibitor, targets immune-mediated platelet destruction in immune thrombocytopenia (ITP) and has demonstrated a favorable safety profile.

A validated XGBoost model identifies psoriasis patients at high hyperglycemia risk, supporting personalized care through a user-friendly web calculator.

Amrita Basu, PhD, says AI can transform health care by streamlining data, enhancing decision-making, and unlocking insights to improve patient outcomes.

Medicare HIV cases are projected to double by 2035, with cumulative costs reaching $195.6 billion and creating critical challenges for federal funding.

Eric H. Yang, MD, emphasizes the need for collaboration and interventions to protect patients’ hearts during breast cancer treatment.

Molecular ESR1 changes may signal symptomatic progression before imaging in metastatic breast cancer, supporting camizestrant for improved quality of life.

Sachin H. Jain, MD, MBA, discusses 2026 health care predictions, including AI adoption, GLP-1 demand, MAHA growth, DEI’s return, and policy shifts.

ASCO GU 2025 had groundbreaking advancements in genitourinary cancer treatments, focusing on prostate cancer, renal cell carcinoma, and health equity.

Reader favorites from the 2025 Patient-Centered Oncology Care conference included articles and interviews featuring AI's role in precision medicine and the importance of collaboration in delivering care.

DeFi trial results show that continuous nirogacestat provides durable tumor control, ongoing shrinkage, sustained symptom improvement, and a stable safety profile over several years.

Discover the latest breakthroughs in multiple sclerosis treatments and research developments shaping the future of MS care in 2025.

Top articles in non–small cell lung cancer (NSCLC) include FDA approvals, improved outcomes due to certain treatments, and updated data presented at conferences.

AI revolutionizes pharmacy by automating workloads, enhancing patient care, and navigating drug pricing challenges amid evolving federal policies.

These pieces highlight several newly approved therapies that expanded treatment options across multiple disease states.

From home-based monitoring and subcutaneous immunotherapy to expanded community cancer networks, 2025 marked a pivotal year in rethinking how cancer care is delivered.